Substrate-reduction therapy with miglustat for glycosphingolipid storage disorders affecting the brain

References

• Kolter T, Sandhoff K. Sphingolipid metabolism diseases. Biochim. Biophys. Acta1758(12), 2057–2079 (2006).
   PubMed Web of Science ®Google Scholar
• Clarke JT. Narrative review: Fabry disease. Ann. Intern. Med.146(6), 425–433 (2007).
   PubMed Web of Science ®Google Scholar
• Winchester B, Vellodi A, Young E. The molecular basis of lysosomal storage diseases and their treatment. Biochem. Soc. Trans.28(2), 150–154 (2000).
   PubMed Web of Science ®Google Scholar
• Cox TM, Schofield JP. Gaucher’s disease: clinical features and natural history. Baillieres Clin. Haematol.10(4), 657–689 (1997).
   PubMed Web of Science ®Google Scholar
• Lachmann RH, Grant IR, Halsall D, Cox TM. Twin pairs showing discordance of phenotype in adult Gaucher’s disease. QJM97(4), 199–204 (2004).
   PubMed Web of Science ®Google Scholar
• Platt FM, Lachmann RH. Treating lysosomal storage disorders: current practice and future prospects. Biochim. Biophys. Acta1793(4), 737–745 (2009).
   PubMedGoogle Scholar
• Neufeld EF. Enzyme replacement therapy. In: Lysosomal Disorders of the Brain. Platt, FM, Walkley SU (Eds). Oxford University Press, Oxford, UK 327–338 (2004).
   Google Scholar
• Boelens JJ. Trends in haematopoietic cell transplantation for inborn errors of metabolism. J. Inherit. Metab. Dis.29(2–3), 413–420 (2006).
   PubMedGoogle Scholar
• Krivit W, Peters C, Shapiro EG. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease Type III. Curr. Opin. Neurol.12(2), 167–176 (1999).
   PubMed Web of Science ®Google Scholar
• Barton NW, Brady RO, Dambrosia JM et al. Replacement therapy for inherited enzyme deficiency – macrophage-targeted glucocerebrosidase for Gaucher’s disease. N. Engl. J. Med.324(21), 1464–1470 (1991).
   PubMed Web of Science ®Google Scholar
• Weinreb NJ, Charrow J, Andersson HC et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am. J. Med.113(2), 112–119 (2002).
   PubMed Web of Science ®Google Scholar
• Rohrbach M, Clarke JT. Treatment of lysosomal storage disorders: progress with enzyme replacement therapy. Drugs67(18), 2697–2716 (2007).
   PubMed Web of Science ®Google Scholar
• Davies EH, Erikson A, Collin-Histed T et al. Outcome of Type III Gaucher disease on enzyme replacement therapy: review of 55 cases. J. Inherit. Metab. Dis.30(6), 935–942 (2007).
   PubMed Web of Science ®Google Scholar
• Radin NS. Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj. J.13(2), 153–157 (1996).
   PubMed Web of Science ®Google Scholar
• Lachmann RH, Platt FM. Substrate reduction therapy for glycosphingolipid storage disorders. Expert Opin. Investig. Drugs10(3), 455–466 (2001).
   PubMed Web of Science ®Google Scholar
• Abe A, Wild SR, Lee WL, Shayman JA. Agents for the treatment of glycosphingolipid storage disorders. Curr. Drug Metab.2(3), 331–338 (2001).
   PubMed Web of Science ®Google Scholar
• Butters TD, Dwek RA, Platt FM. Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses. Glycobiology15(10), 43R–52R (2005).
   Web of Science ®Google Scholar
• Fischl MA, Resnick L, Coombs R et al. The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200–500 CD4 cells/mm3. J. Acquir. Immune Defic. Syndr.7(2), 139–147 (1994).
   PubMed Web of Science ®Google Scholar
• Platt FM, Neises GR, Dwek RA, Butters TD. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J. Biol. Chem.269(11), 8362–8365 (1994).
   PubMed Web of Science ®Google Scholar
• Cox T, Lachmann R, Hollak C et al. Novel oral treatment of Gaucher‘s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet355(9214), 1481–1485 (2000).
   PubMed Web of Science ®Google Scholar
• Platt FM, Neises GR, Reinkensmeier G et al. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science276(5311), 428–431 (1997).
   PubMed Web of Science ®Google Scholar
• Jeyakumar M, Butters TD, Cortina-Borja M et al. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc. Natl Acad. Sci. USA96(11), 6388–6393 (1999).
   PubMed Web of Science ®Google Scholar
• Vanier MT, Millat G. Niemann–Pick disease type C. Clin. Genet.64(4), 269–281 (2003).
   PubMed Web of Science ®Google Scholar
• Liscum L, Sturley SL. Intracellular trafficking of Niemann–Pick C proteins 1 and 2: obligate components of subcellular lipid transport. Biochim. Biophys. Acta1685(1–3), 22–27 (2004).
   PubMed Web of Science ®Google Scholar
• Walkley SU. Secondary accumulation of gangliosides in lysosomal storage disorders. Semin. Cell. Dev. Biol.15(4), 433–444 (2004).
   PubMed Web of Science ®Google Scholar
• Zervas M, Somers KL, Thrall MA, Walkley SU. Critical role for glycosphingolipids in Niemann–Pick disease type C. Curr. Biol.11(16), 1283–1287 (2001).
   PubMed Web of Science ®Google Scholar
• Elliot-Smith E, Speak AO, Lloyd-Evans E et al. Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis. Mol. Genet. Metab.94(2), 204–211 (2008).
   PubMed Web of Science ®Google Scholar
• Yam GH, Zuber C, Roth J. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder. FASEB J.19, 12–18 (2005).
   PubMed Web of Science ®Google Scholar
• Fan JQ. A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity. Biol. Chem.389, 1–11 (2008).
   PubMed Web of Science ®Google Scholar
• Bembi B, Marchetti F, Guerci VI et al. Substrate reduction therapy in the infantile form of Tay-Sachs disease. Neurology66(2), 278–280 (2006).
   PubMedGoogle Scholar
• Capablo JL, Franco R, de Cabezon AS et al. Neurologic improvement in a Type 3 Gaucher disease patient treated with imiglucerase/miglustat combination. Epilepsia48(7), 1406–1408 (2007).
   PubMed Web of Science ®Google Scholar
• Schiffmann R, Fitzgibbon EJ, Harris C et al. Randomized, controlled trial of miglustat in Gaucher‘s disease Type 3. Ann. Neurol.64(5), 514–522 (2008).
   PubMed Web of Science ®Google Scholar
• Garbutt S, Harwood MR, Harris CM. Comparison of the main sequence of reflexive saccades and the quick phases of optokinetic nystagmus. Br. J. Ophthalmol.85(12), 1477–1483 (2001).
   PubMedGoogle Scholar
• Lachmann RH, te Vruchte D, Lloyd-Evans E et al. Treatment with miglustat reverses the lipid-trafficking defect in Niemann–Pick disease type C. Neurobiol. Dis.16(3), 654–658 (2004).
   PubMed Web of Science ®Google Scholar
• Chien YH, Lee NC, Tsai LK et al. Treatment of Niemann–Pick disease type C in two children with miglustat: initial responses and maintenance of effects over 1 year. J. Inherit. Metab. Dis.30(5), 826 (2007).
   PubMed Web of Science ®Google Scholar
• Santos ML, Raskin S, Telles DS et al. Treatment of a child diagnosed with Niemann–Pick disease type C with miglustat: a case report in Brazil. J. Inherit. Metab. Dis. (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Paciorkowski AR, Westwell M, Ounpuu S et al. Motion analysis of a child with Niemann–Pick disease type C treated with miglustat. Mov. Disord.23(1), 124–128 (2008).
   PubMedGoogle Scholar
• Galanaud D, Tourbah A, Lehericy S et al. 24 month-treatment with miglustat of three patients with Niemann–Pick disease type C: follow up using brain spectroscopy. Mol. Genet. Metab.96(2), 55–58 (2009).
   PubMed Web of Science ®Google Scholar
• Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat for treatment of Niemann–Pick C disease: a randomised controlled study. Lancet Neurol.6(9), 765–772 (2007).
   PubMed Web of Science ®Google Scholar
• Morgan C, Adams D, Tifft C. Miglustat improves function in juvenile GM1 gangliosidosis: in vitro evidence for a molecular chaperone effect. Presented at the 57th Annual Meeting of the American Society of Human Genetics. San Diego, CA, USA, 23–27 October 2007.
   Google Scholar